Clinical Guest Contributors

  1. What Can We Expect From The FDA In 2026? 10/20/2025

    Expert panelists at the 2025 RAPS Convergence discussed what lies ahead for the FDA in 2026.

  2. We Need Communication Beyond The "Blah, Blah, Blah" 10/20/2025

    Miscommunication can derail clinical trials and lengthen study timelines. Discover how to improve communication among sponsors, CROs, and sites, and thus run more effective clinical trials.

  3. 100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing 10/17/2025

    Research Manager Mathini Ilancheran explores the effects of U.S. drug tariffs on global supply chains, multinational pharma firms, and critical partners across drug development.

  4. What Is Disease Progression Modeling, And When Is The Right Time To Use It? 10/16/2025

    With the help of Clinical Trials Transformation Initiative's Lindsay Kehoe, discover how disease progression modeling can improve trial efficiency, inform precision medicine, assist in regulatory decision-making, and more.

  5. Diverse Enrollment — Ahem, "Biological Variability" — Gets Widespread Support At RAPS Convergence 10/16/2025

    DEI, diverse enrollment, biological variability -- whatever you call it, industry leaders at RAPS Convergence discussed their unwavering support of it when it comes to executing clinical trials that align "good science" with "the right thing to do."

  6. Whole-Body MRI Biomarkers Unlock A Fuller Picture In Neuromuscular Trials 10/15/2025

    Discover the utility and promise of whole-body MRIs a digital biomarkers in neuromuscular clinical trials.

  7. Trends In Rare Disease Trials: Evaluating Trial Types' Pros, Cons, And Adoption Rates 10/14/2025

    In the second article of the series, Beroe Inc. Lead Analyst Sapna Rani provides a comprehensive evaluation of leading trial types for rare disease development and compares adoption rates, design-specific trade-offs, and practical selection criteria.

  8. Trends In Rare Disease Trials: Trial Designs, Challenges, And Regulatory Progress 10/13/2025

    Beroe Inc. Lead Analyst Sapna Rani unpacks the evolution of trial design types in rare disease research, analyzes ongoing challenges, and examines how regulatory support is enabling innovation in part one of this three-part series.

  9. How Enveric Biosciences Is Prepping For Its First IND 10/10/2025

    Enveric Biosciences CEO Joseph Tucker, Ph.D., discusses how the team is finalizing IND-enabling studies, leveraging both in-house expertise and trusted external partners.

  10. Oncology PI Shares Lessons Learned And Successes Working With Basic Scientists 10/9/2025

    Ranee Mehra, MD, shares her successes and discusses how they shape her approach to future research, as well as details the importance of working closely with basic scientists.